tldrdailynews.com logo

FDA Clears Non-Antipsychotic Help for Agitation in Alzheimer’s Dementia

1 min read
Source: fda.gov
FDA Clears Non-Antipsychotic Help for Agitation in Alzheimer’s Dementia
Photo: fda.gov
TL;DR Summary

The FDA expanded the use of Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) to treat agitation in adults with Alzheimer’s disease–related dementia, marking the first non-antipsychotic approved for this symptom. In two randomized trials, Auvelity improved agitation measures and extended time to relapse with continued treatment. Common side effects include dizziness, upset stomach, headache, diarrhea, drowsiness, dry mouth, sexual dysfunction, and sweating; there is a boxed warning for suicidality in adolescents/young adults and risks of seizures, high blood pressure, and mood activation. Pre-treatment assessments include blood pressure checks and bipolar-history screening. The approval was granted to Axsome Therapeutics, supported by breakthrough therapy and priority review designations.

Topics:business#agitation-in-dementia#alzheimers-disease#auvelity#fda-approval#health#non-antipsychotic
Share this article
  1. FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia  fda.gov
  2. FDA Approves Auvelity for Treatment of Agitation in Alzheimer Disease  Psychiatric Times
  3. Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease  Yahoo Finance
  4. US FDA approves Axsome's drug for Alzheimer's-related agitation  Reuters
  5. Axsome's Auvelity is first non-antipsychotic cleared in US for Alzheimer's agitation  FirstWord Pharma

Reading Insights

Total Reads

0

Unique Readers

6

Time Saved

3 min

vs 4 min read

Condensed

83%

616 → 105 words

Want the full story? Read the original article

Read on fda.gov